TwoStep Therapeutics has emerged from stealth mode with a $62.5 million Series A financing round backed by the venture arms of Pfizer and Merck KGaA, positioning the company as a new contender in the fast-evolving antibody-drug conjugate space. The startup is developing a novel class of peptide-drug conjugates (PDCs) that could offer significant manufacturing and pharmacological advantages over traditional ADCs, creating fresh demand for specialized peptide synthesis and payload manufacturing capabilities across the contract development and manufacturing organization landscape. The financing round was co-led by Pfizer Ventures and Merck KGaA's M Ventures, with participation from several undisclosed life science venture funds.

The company's lead program targets integrin receptors overexpressed on solid tumors using a proprietary peptide scaffold conjugated to the well-characterized MMAE cytotoxic payload. Unlike conventional ADCs that rely on large monoclonal antibodies for tumor targeting, PDCs use short synthetic peptides typically 10 to 20 amino acids in length, which are significantly cheaper and faster to manufacture. TwoStep plans to advance its lead candidate into Phase 1 clinical trials before the end of 2026, with initial safety and pharmacokinetic data expected in the first half of 2027. The company has disclosed that its proprietary conjugation chemistry achieves a drug-to-peptide ratio optimized for both efficacy and stability in circulation.

For API and intermediate suppliers, the rise of PDCs represents a meaningful shift in manufacturing requirements. Traditional ADC production demands complex antibody expression systems, site-specific conjugation chemistry, and stringent containment for potent cytotoxic payloads. PDC manufacturing, by contrast, relies on solid-phase peptide synthesis, a well-established process that numerous contract manufacturers worldwide already support. The peptide backbone can be produced at scale using standard Fmoc or Boc chemistry, potentially reducing production costs by an order of magnitude compared to antibody-based conjugates. This cost advantage could be transformative for companies seeking to bring targeted oncology therapies to markets with limited healthcare budgets.

However, the payload component of PDCs still requires specialized handling. MMAE, the microtubule-disrupting agent used in TwoStep's lead candidate, is a highly potent compound with occupational exposure limits in the nanogram range. Contract manufacturers with established high-potency API capabilities and validated containment suites will be best positioned to capture this emerging demand. Companies like Lonza, Piramal Pharma Solutions, and Catalent that have invested heavily in ADC-specific infrastructure may find their expertise directly transferable to PDC production. The linker chemistry connecting peptide to payload also requires expertise in click chemistry and bioconjugation, skills that are concentrated among a relatively small number of specialized CDMOs.

The involvement of both Pfizer and Merck KGaA as investors signals strong pharmaceutical industry confidence in the PDC modality. Pfizer has been aggressively building its oncology pipeline through both internal development and external partnerships, while Merck KGaA's EMD Serono division has deep expertise in targeted cancer therapies. Their participation provides TwoStep not only with capital but also with potential pathways to future licensing or co-development agreements that could accelerate scale-up and commercial manufacturing timelines. Industry analysts note that strategic investor involvement at the Series A stage often precedes larger partnership deals once clinical proof-of-concept is established.

The broader ADC market has experienced explosive growth, with global sales exceeding $12 billion in 2025 and projected to surpass $30 billion by 2030. This growth has strained manufacturing capacity, particularly for the specialized bioconjugation and fill-finish steps required for traditional ADCs. PDCs could alleviate some of this capacity pressure by shifting a portion of targeted conjugate production to the more scalable peptide synthesis infrastructure that already exists at numerous facilities worldwide. The peptide therapeutics market itself is projected to reach $50 billion by 2028, and PDCs sit at the intersection of two high-growth segments.

TwoStep's approach also addresses a key limitation of conventional ADCs: the bystander effect and tumor penetration. Large antibody molecules face significant diffusion barriers in solid tumors, often limiting efficacy to antigen-expressing cells at the tumor periphery. Smaller peptide conjugates can penetrate more deeply into tumor tissue, potentially achieving more uniform drug distribution. This pharmacological advantage could expand the addressable patient population beyond what current ADC therapies can reach. Additionally, the faster blood clearance of peptide conjugates may reduce systemic toxicity, a common concern with ADCs that release payload during prolonged circulation.

For pharmaceutical procurement teams and supply chain strategists, the emergence of PDCs as a validated therapeutic modality warrants close monitoring. If TwoStep's Phase 1 data confirms the expected safety and efficacy profile, the platform could attract significant partnering interest from large pharmaceutical companies seeking differentiated oncology assets. This would likely trigger a wave of manufacturing capacity investment and potentially reshape the competitive landscape for contract manufacturing services in the targeted conjugate space. Early engagement with TwoStep's supply chain team could position CDMOs favorably for future commercial manufacturing contracts.

The Series A financing will fund TwoStep through Phase 1 proof-of-concept data and support expansion of its manufacturing capabilities. The company has indicated plans to establish both internal process development capacity and strategic partnerships with contract manufacturers for clinical and eventual commercial-scale production. Industry observers note that the speed and cost advantages of PDC manufacturing could enable TwoStep to move more quickly through clinical development than traditional ADC companies, compressing the typical timeline from first-in-human to pivotal trials. The modular nature of the PDC platform also allows rapid iteration on peptide sequences and payloads, enabling a pipeline expansion strategy that could generate multiple clinical candidates from a single manufacturing infrastructure.

As the pharmaceutical industry continues to seek more efficient and scalable approaches to targeted oncology therapy, peptide-drug conjugates represent a compelling evolution of the ADC paradigm. TwoStep's well-capitalized entry into clinical development, backed by two of the world's largest pharmaceutical companies, marks an important validation point for the PDC platform and signals growing confidence that these next-generation conjugates can deliver on their manufacturing and therapeutic promise. Contract manufacturers with peptide synthesis expertise should begin preparing for increased demand as this modality matures, while ADC-focused CDMOs should evaluate whether their existing capabilities can be adapted to serve the emerging PDC market segment.